Logo image
Dynamic cytokine monitoring enhances CAP severity scores in elderly patients: a prospective pilot study
期刊文章   開放取用(OA)

Dynamic cytokine monitoring enhances CAP severity scores in elderly patients: a prospective pilot study

C.-H. Chen, Y.-T. Lee, C.-F. Shen 和 C.-M. Cheng
Internal and Emergency Medicine, 卷.21(2), 頁碼.653-664
2026
Web of Science ID: WOS:001497087700001

摘要

Community-acquired pneumonia Cytokine dynamics Elderly Interleukin-6 Mortality prediction Risk stratification
Current severity scoring systems (PSI and CURB-65) have limitations in risk stratification for elderly patients with community-acquired pneumonia (CAP). Given the complex immune responses in elderly populations, dynamic biomarker monitoring may provide additional prognostic value. This study evaluates whether integrating early cytokine dynamics with traditional severity scores improves mortality prediction in elderly CAP patients. This prospective observational study included 81 CAP patients aged ≥ 65 years. Multiple cytokines were measured at admission and within 48 h. Traditional severity scores (PSI and CURB-65) were calculated at baseline. Patients were categorized into survival (n = 67) and mortality (n = 14) groups. The predictive value of cytokine dynamics alone and in combination with severity scores was assessed using ROC curve analysis. Among measured cytokines, IL-6 demonstrated significant prognostic value. The mortality group showed an 88% increase in IL-6 levels within 48 h, contrasting with a 49% decrease in survivors (p = 0.040). While individual PSI (AUC = 0.6631) and CURB-65 (AUC = 0.6231) showed modest discrimination, integration with IL-6 dynamics significantly improved predictive accuracy (PSI + IL-6: AUC = 0.7676, p = 0.0017; CURB-65 + IL-6: AUC = 0.7564, p = 0.0027). Early dynamic monitoring of cytokines, particularly IL-6, significantly enhances the prognostic accuracy of traditional severity scores in elderly CAP patients. This pilot study suggests that this integrated approach provides a more precise risk stratification tool, potentially enabling more personalized clinical decision-making. Larger multicenter studies are warranted to validate these findings and establish standardized cutoff values for clinical implementation. © The Author(s) 2025.

檔案與連結 (2)

url
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105006794117&doi=10.1007%2fs11739-025-03975-7&partnerID=40&md5=f3b058153624174f63285cc7a1213d25檢視
url
https://doi.org/10.1007/s11739-025-03975-7檢視
已出版(紀錄版本) 開放

相關連結

InCites亮點

本研究成果之相關指標(擷取自 InCites Benchmarking & Analytics)

合作類型
機構合作
引用書目主題
1 Clinical & Life Sciences
1.23 Infection Management & Resistance
1.23.347 Streptococcus Pneumoniae
Web Of Science研究領域
Respiratory System
ESI研究領域
Clinical Medicine

聯合國永續發展目標(SDGs)

此研究成果有助於達成以下目標:

#3 Good Health and Well-Being

來源:來自InCites的SDGs

詳細資料

Logo image